Endocrine Tumours Lab, Program of Predictive and Personalized Medicine of Cancer (PMPPC), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital, Badalona, Spain.
Front Endocrinol (Lausanne). 2021 Mar 15;12:646210. doi: 10.3389/fendo.2021.646210. eCollection 2021.
Epithelial-mesenchymal transition (EMT) is a dynamic process by which epithelial cells loss their phenotype and acquire mesenchymal traits, including increased migratory and invasive capacities. EMT is involved in physiological processes, such as embryogenesis and wound healing, and in pathological processes such as cancer, playing a pivotal role in tumor progression and metastasis. Pituitary tumors, although typically benign, can be locally invasive. Different studies have shown the association of EMT with increased tumor size and invasion in pituitary tumors, and in particular with a poor response to Somatostatin Receptor Ligands (SRLs) treatment in GH-producing pituitary tumors, the main cause of acromegaly. This review will summarize the current knowledge regarding EMT and SRLs resistance in acromegaly and, based on this relation, will suggest new biomarkers and possible therapies to SRLs resistant tumors.
上皮-间充质转化（EMT）是一个动态的过程，在此过程中，上皮细胞丧失其表型并获得间充质特征，包括增加的迁移和侵袭能力。EMT 参与生理过程，如胚胎发生和伤口愈合，以及病理过程，如癌症，在肿瘤进展和转移中发挥关键作用。垂体肿瘤虽然通常是良性的，但可能具有局部侵袭性。不同的研究表明 EMT 与垂体肿瘤的肿瘤增大和侵袭增加有关，特别是与生长激素分泌性垂体肿瘤对生长抑素受体配体（SRLs）治疗的反应不良有关，这是肢端肥大症的主要原因。这篇综述将总结关于肢端肥大症中 EMT 和 SRLs 耐药性的最新知识，并根据这种关系，提出新的生物标志物和可能的治疗方法来治疗 SRLs 耐药性肿瘤。
